Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Stellar Biotechnologies, Inc. (SBOTF) CEO Presents at Renshaw 2014 Global Investment Conference

Stellar Biotechnologies president and CEO Frank Oakes today presented at the Rodman & Renshaw 2014 Global Investment Conference, where more than 200 biotech, healthcare, technology, natural resources and growth companies are presenting to an audience of more than 1,500 attendees. The conference will be held at the New York Palace Hotel in New York City, September 8-11, 2014.

Oakes took the stage to highlight the Stellar’s position and operations a sustainable manufacturer of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets.

This versatile molecule can be combined with a disease-targeting agent to create a novel immunotherapy, or used alone to assess the body’s immune response.  KLH can only be obtained from a scarce marine source, the Giant Keyhole Limpet, a shelled species native to Southern California and Mexico.

Stellar has developed a patented method for harvesting KLH without harming the Giant Keyhole Limpet.  The company’s production facilities represent breakthrough achievements such as the first-ever ability to sustain generations of the source in controlled, land-based facilities.

Stellar aims to utilize this method to meet the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production and developing KLH-based active immunotherapies.

The webcast of Oakes presentation is archived on Stellar’s website at:

Visit and the KLH knowledge base

Posted in Small Cap News | Leave a comment

SeeThruEquity Issues Positive Outlook, Reiterates Price Target for Net Element, Inc. (NETE)

Independent equity research firm SeeThruEquity this morning reiterated its price target for and issued a positive Q2 2014 update on Net Element, a global financial company specializing in mobile payments and transactional services in emerging countries and in the United States. The research firm highlights the company’s first quarter of profitability, significant debt reduction, extended financing and recent board expansion.

“We continue to be impressed with NETE’s execution and remain confident about NETE’s growth potential over the next 2-3 years,” Ajay Tandon, CEO of SeeThruEquity stated in the update. “On July 2, 2014, NETE announced the closing of a $10mn credit facility from the payments industry-leading lender, RBL Capital Group, LLC. NETE also continues to expand its board with the inclusion of industry veterans … Our price target remains $3.47 per share.”

The price target is more than double Net Element’s current trade around $1.51.

The research firm also noted Net Element’s first-quarter performance in which the company reported its first quarter of profitability, recording Q2 net income of $1.3 million, or $0.04 per share, and a reduction of its liabilities by 40% to $22.8 million.

In July 2014, RBL Capital extended Net Element an additional credit facility under which it can borrow up to $10.0 million, representing the second funding in the $30 million financing round that was announced in April 2014.

“We believe this new financing will allow NETE to accelerate its growth initiatives in Russia and other emerging markets,” stated SeeThruEquity.

The research firm also highlighted Net Element’s recent appointments of Drew Freeman and William Healy to its board of directors. Freeman has more than 30 years of electronic payments and merchant services industry experience. Healy brings to the table more than 24 years of merchant financing and electronic payments industry experience. He currently serves as the president of Funds4Growth, a leading investment firm focused on financing of payment service providers in the United States. Since launching Funds4Growth, Healy has successfully structured and financed in excess of $100 million in merchant base loans.

To view the entire update visit:!nete/c1e5c

For more information visit

Posted in Nete Element Inc. NETE | Leave a comment

Continental Stock Transfer Leadership Serve as Bedrock of Operations

They say that a chain is only as strong as its weakest link. In the public marketplace, weak simply doesn’t cut it. From public companies to stock transfer agents, success hinges upon management’s ability to utilize their expertise, experience and ability to define and execute a plan of operations that ultimately benefits shareholders.

In its 50 years of business, Continental Stock Transfer has established a powerful roster of team leaders, each with extensive knowledge in their respective fields. Together, these individuals serve companies with up to 50,000 shareholders with a range of fundamental offerings, including record keeping, maintaining shareholder information, issuance and transfer of shares, shareholder communication, dividend disbursement and tax reporting, stock plan administration, escrow services, annual meeting and proxy services and much more.

Continental’s operations are spearheaded by company President and Chairman Steven Nelson, a 30-year industry veteran and attorney with experience in public and private practice. He is a member of the New York State and Federal Bars, and has practiced as a federal prosecutor, and chairs the Legal committee of the Securities Transfer Association Board, active in promoting important changes within the industry. Nelson is entrusted with Continental’s day-to-day organizational and administrative issues, as well as overall management of client initiatives.

In his 30 years with Continental, Donald Gress has amassed detailed knowledge of all operational and regulatory issues. He currently serves as vice president, chief operating officer and secretary, leveraging his extensive industry expertise to direct Continental’s core co-agency relationships, guiding all Internet-related operations, and acting as the interface between the company’s department and programming support staff.

Compliance is of immeasurable value in the public marketplace, and Continental’s chief financial officer and Compliance Officer Frank DiPaolo facilitates regulatory compliance on behalf of the company as well as coordinates risk management and internal audit programs. DiPaolo joined Continental in 2000 and is tasked with oversight of day-to-day financial activities of the company as well as its institutional relationships with banks and brokers. DiPaolo has 30 years of experience in the banking industry with a resume of employment with some of the world’s largest banks.

Continental’s shareholder services are headed by the division’s director and Vice President Mark Zimkind, who has more than 25 years of industry experience at several large bank transfer agents. Zimkind oversees account administration, corporate actions, stock transfer and investment plan services. He has facilitated some of the largest and most complex mergers, working on more than 2,000 different merger transactions in his career.

The aforementioned players, along with several other members of the company’s core leadership, continues to build upon Continental’s decades of industry experience to provide small-cap companies with the same quality of services expected by their large-cap counter parts.

For more information, visit

Let us hear your thoughts below:

Posted in Small Cap News | Leave a comment

Net Element International (NETE) Rides Successful Acquisitions toward Mobile Commerce Dominance

It’s hard to realize that in most emerging countries the phrase “electronic payments” means something appreciably different than it does in the U.S. and other fully developed nations. In those emerging and rapidly developing economies, electronic commerce is largely based on mobile SMS or smartphone-technology, and banking transactions quite disparate from the plastic-centric, online payment platforms common in the Western world. Notably, SMS-based financial transactions are reported as being largely responsible for the triple-digit growth of cashless transactions around the world.

In Russia, where Net Element International subsidiary TOT Money is a leader in providing Premium SMS and Mobile Commerce solutions for major enterprises like VimpelCom — the nation’s second-largest telecom — and smaller businesses, E-Wallet sales are expected to near $35 billion rubles by the end of 2014. Revenue anticipated from SMS-enabled purchase and banking transactions is anticipated to reach $1.5 billion.

Tot Money is a component of NETE’s Tot Group, Inc., which also includes companies such as Unified Payments, a U.S. based $10-billion payment and money-management enabler named 2012’s “fastest-growing private company” by Inc. Magazine in recognition of its 23,646-percent three-year growth record.

In Russia and countries with similar economic cultures, TOT leverages the fact that the mobile telephone is by far the instrument of choice for online-purchasing, bill-paying and banking transactions. In many corners of the world, the actual preference for payment via smartphone SIM Cards can be literally staggering. In fact, more than three-to-one in Russia, where the over 227 million active SIM-card accounts are capable of handling cashless transactions dwarfs the 73.8 million internet accounts able to perform similar money-management chores.

“In 2011 the amount of carrier payments was 6.6 billion rubles and, by 2012, this jumped 44% to 9.5 billion rubles,” J’son & Partners Consulting reported. “This growth trajectory continues unabated … (we predict) that by 2017 the market of mobile operator payments in Russia will exceed 40 billion rubles. All of this bodes well for TOT, given their growing market share in a region that is enjoying tremendous growth with a population that has wholeheartedly embraced SMS services.”

According to NETE CEO Oleg Firer, “We are in the right place, at the right time, with the right solution, and that is why we are providing payment-processing services to the over 60 million subscribers of VimpelCom in Russia.”

Noting that TOT Money became VimpelCom’s top SMS contributor within six months of entering the market, Firer said, “We expected to become a leading value-added services provider for the $1.5-billion Russian SMS-payments market and the $475-million Russian mobile-commerce market, and that is exactly what we have accomplished.”

TOT Money, however, is far from being Net Element’s only subsidiary, and Russia and the Commonwealth of Independent States (CIS) created by former Soviet Union satellites are a long way from being its only markets. In fact, Firer and his associates have displayed an uncanny ability to find and fill needs for high-tech, out-of-the-box, mobile money-management solutions worldwide. Even in countries like the U.S. with its 90-plus percent internet penetration.

This extraordinary knack for finding opportunities competitors may have overlooked is a key reason why the company increased its gross profit by more than 900 percent between 2012 and 2013 and seems poised to deliver major returns to its shareholders in the very short term.

Adding to its U.S. holdings, NETE, via the TOT Group, has announced the acquisition of QuickPay, a Florida-based firm serving the needs of what the U.S. Federal Deposit Insurance Corp. defines as unbanked or under-banked consumers in the U.S. and eight other countries.

Within its potential market of several hundred million users — 28 million U.S. households alone, according to the FDIC — Quickpay enables users to order products and pay home-utility bills, cell-phone bills, and make cash transfers through conveniently located machines that operate a lot like ATMs and look a lot like Red Box DVD-vending machines.

In a 2013 expansion move, NETE acquired Aptito, a multinational, Miami-based provider of the mPOS all-in-one cloud-based information, ordering, reservation, and payment solution for the hospitality industry. Powered by a tablet computer, mPOS “combines traditional POS functionality with mobile ordering, payments, social media, intelligent offers, mobile applications, loyalty, and transactional data all in one solution with Aptito’s cloud-based payments platform at the center of it all,” as stated by the company. Using the system, food and beverage servers can place orders directly from their mobile phones and accept payments right at table-side to facilitate faster service, quicker table turnarounds, and less waiting time for customers.

Aptito also offers a mobile app for empowering a Self-Ordering Apple® iPad®-based kiosk to allow restaurant owners to offer customers a fast, convenient alternative to waiting for a server to reach their table and take an order. “Aptito is an ideal solution for our hospitality merchants who are anxious to increase revenue per table and grow their customer base,” Firer said. “Restaurants world-wide are facing similar challenges to acquire new customers, maximize the spend per visit and improve customer service while reducing staff costs. This acquisition will be a strategic addition to TOT Group and one that delivers a compelling solution and a competitive edge.”

In another significant 2014 transaction, NETE successfully negotiated a $10-million credit facility from RBL Capital Group LLC. Approximately $3 million will be used to pay NETE’s outstanding debt to MBF Merchant Capital in full, thereby significantly reducing Net Element’s total outstanding debt. The balance will be utilized, Firer said, to “enhance our ability to capture market opportunities and create shareholder value.”

“We are pleased to be supporting Net Element’s growth efforts,” said RBL Capital spokesman William W. Williams. “Merchants and consumers will continue to shift to a cashless environment and we see Net Element as an emerging leader in mobile payments, value-added services and technologies.”

With, according to analysts at McKinsey & Company, “more than a billion people in emerging and developing markets having cell phones but no bank accounts” and, in Ernst & Young’s words, “the universe of mobile payments services expanding rapidly as boundaries blur between payments, marketing, and shopping services delivered via mobile,” Net Element International is in the highly enviable position of being a major player in a virtually no-limits industry.

Are more “fastest-growing” accolades in the offing? We’ll just have to wait and see.

Posted in Small Cap News | Leave a comment

Continental Stock Transfer & Trust – Offering More than “Business as Usual”

Continental Stock Transfer & Trust is a major stock transfer agent specializing in growth and emerging companies. The company fully utilizes its 50-year history in the industry to react with stability and agility to client needs.

Working with Continental is rarely “business as usual.” Transfer agents may perform the same basic functions but Continental goes above and beyond to be the agent of choice. As the only major transfer agent focused on small to midsize emerging and growth companies, the company supports its clients’ unique needs without question and beyond expectations. For Continental, this means going the extra mile to execute exactly what clients need, when they need it.

Continental is committed to serving companies with up to 50,000 shareholders with experience, knowledge, and foresight. The firm emphasizes the kind of specialized service that small publicly traded companies cannot always get from a transfer agent: personal access to senior staff, flexible offerings, innovative technology, exceptional execution, and an unmatched value based on five decades of industry experience. This foundation, along with a team of tested professionals, is what allows Continental to react promptly and deftly to its clients, and to conceive and flawlessly carry out the services best suited to each client.

Continental’s priority is to provide issuers and shareholders with immediate answers and expert resources, such as round-the-clock online account access from desktops, laptops or mobile devices and a secure, high-performance technology platform that makes it simple for shareholders to vote their proxy.

As a transfer agent, Continental serves as a critical record keeper, maintaining shareholder information, including: names, addresses, taxpayer IDs, and certificate, book-entry, and share detail.

The company also skillfully:

• Communicates with shareholders on a client’s behalf
• Handles restricted and legal transfers
• Handles dividend disbursement and tax reporting
• Interfaces with the Depository Trust & Clearing Corporation and stock exchanges
• Issues and transfers shares
• Maintains a history of stock issuance and cost basis
• Provides issuer and shareholder round-the-clock online account access
• Reports on shareholder and stock activity

In addition to its fundamental offerings, Continental has extended offerings that could be customized for its clients and their shareholders. These include:

• Annual meeting and proxy services
• Corporate actions and escrow services
• Dividend Disbursement Services
• Dividend reinvestment plan and direct stock purchase plan administration
• Employee plan administration
• Stock plan administration

For more information, visit

Let us hear your thoughts below:

Posted in Small Cap News | Leave a comment

Net Element, Inc. (NETE) Poised to Capture Sizeable Share of Mobile Payment Processing Market at Home and Abroad

Net Element is a technology-driven company focused on mobile payments and value-added transactional services in emerging countries and in the United States. To drive its revenue, NETE operates a global mobile payments and transaction processing provider known as TOT Group that includes Unified Payments, recognized by Inc. Magazine as the #1 Fastest Growing Private Company in America in 2012; Aptito, a cloud-based point of sale (POS) payments platform; and TOT Money, which has a leading position in Russia and has been ranked as the best SMS content provider by Beeline, the second largest telecom operator there.

In cooperation with its subsidiaries, Net Element provides ecommerce and value-added features to mobile commerce environments. By way of its global development centers and strong business relationships in the US, Russia, and Commonwealth of Independent States, the company is set in place for growth going forward.

The company endeavors to be a worldwide publisher of online destinations and business services on a technology platform specifically designed for Internet and mobile distribution. The platform is leveraged as a springboard for rapid development, production, and distribution of high-definition and three-dimensional media content. Additionally, the company creates social and business communities in motorsports, music, film and entertainment through the ownership if its internet properties.

NETE’s brand line-up includes,,,, and Simply stated, the company plans to transform the online experience. Their team consists of individuals equipped with years of experience in the various fields of technology, marketing, architecture, intellectual property, law, creative writing, product design, and all forms of digital and print media.

At the helm of the company’s management group is Chief Executive Officer Oleg Firer. Mr. Firer is responsible for the strategy and execution of the company’s mission of invigorating global commerce. Before his tenure at Net Element, Mr. Firer served as Executive Chairman of Unified Payments and has led the company from its launch to its acquisition by TOT Group in April of 2013. Under his leadership, Unified Payments’ revenues grew an astonishing 23,646% over 3 years. Further, the company was ranked as fastest-growing company by Inc. Magazine in 2012. In his business activity prior to Unified Payments, Mr. Firer held senior leadership posts in payment processing, private equity, and wireless communications. Impressively, Mr. Firer was acknowledged by Forbes as one of the 5 Incredible Entrepreneurs and by Business Leader Magazine as a Top Entrepreneur in South Florida. Additionally, Mr. Firer was named by Poder Magazine as one of the Most Influential People in Miami and recognized by Inc. Magazine as the founder of the fastest-growing private company in 2012. Mr. Firer serves as a board member of Net Element and a member of the Electronic Transactions Association (ETA) Mobile Payments, ISO Practices and Risk, Fraud & Security committees.

The company provides the technology and services that businesses require to accept cashless transactions for the SME business under the Unified Payments brand. NETE processes cashless transactions for card-present or card-not-present transactions, including point-of-sale, mobile POS, Internet businesses, service-oriented businesses, and mail order/telephone order merchants, as well as checks and direct debits.

The company also provides Aptito, a mPOS and value-added services technology, which helps restaurants drive consumer engagement through tablet, mobile, and other cloud-connected devices. Aptito provides hospitality merchants with tools to increase sales, productivity, and customer loyalty. In addition, it offers carrier-integrated mobile payments solutions, including in-app, premium SMS, online, and carrier billing.

Further, the company provides engineering services to its payment processing and mobile payment solutions business. Net Element, Inc., together with its subsidiaries, enables ecommerce and content-management companies to monetize their assets in ecommerce and mobile commerce environments.

Mobile payments are known for strengthening relationships between those who sell and those who buy, as merchants are offering more convenience and customers are staying loyal because of it. But merchants and customers are both curious about who is interested in mobile payments and just how the industry is coming into focus. Net Element, Inc.’s work to date, through its global market strategy, is placing its name in the middle of the discussion that leads to internal growth and cutting-edge solutions for its customers.

For more information, visit

Posted in Small Cap News | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Receives Notice of Allowance for Stem Cell Technology

Today before the opening bell, VistaGen Therapeutics announced its reception of a Notice of Allowance from the Canadian Intellectual Property Office. The Notice of Allowance enables further expansion of VistaGen Therapeutics’ intellectual property portfolio, which consists of pluripotent stem cell culture systems that produce human cells of the endoderm lineage, including liver, lung, pancreas, parathyroid and thyroid cells.

The notice pertains to Canadian Patent Application No. 2,487,058, which is exclusively licensed to VistaGen Therapeutics by the Icahn School of Medicine at Mt. Sinai in New York and entitled “Mesoderm and Definitive Endoderm Cell Populations”. This new development builds on VistaGen Therapeutics’ recent reception of another Notice of Allowance for Canadian Patent Application 2,684,022, both of which strengthen the company’s intellectual property portfolio relating to a number of pluripotent stem cell projects VistaGen Therapeutics has been considering pursuing in Canada.

These include: projects that involve liver safety and liver toxicity-based drug rescue; customized drug discovery assays for therapies to treat liver disease and diabetes; and exploratory nonclinical studies for potential regenerative medicine applications involving beta islet cells and other cells of the endoderm lineage.

A biotechnology company, VistaGen Therapeutics is focused on using pluripotent stem cell technology for applications in drug rescue, drug discovery, and regenerative medicine.

For more information, visit:

Let us hear your thoughts:

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

VistaGen Therapeutics, Inc. (VSTA) Provides Reverse Stock Split FAQs

Last week, VistaGen Therapeutics implemented a 1-for-20 reverse split of its common stock. As a result, the number of shares of the company’s common stock outstanding was reduced from approximately 25.5 million to approximately 1.2 million. Because the stock price went up appropriately, the split did not affect any stockholder’s ownership percentage or total market value at the time it was implemented.

The reverse stock split is intended to increase market awareness of VistaGen’s common stock and position the company for potential future listing of its common stock on a national securities exchange. A number of other reasons are listed at the new FAQs page recently posted at

To view the original press release announcing the split, visit

For those unfamiliar with the company, VistaGen Therapeutics is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.

More information on the company and its technology can be found at

Posted in VistaGen Therapeutics Inc. VSTA | Leave a comment

MeetMe, Inc. (MEET) Adds New Board Member with Digital Media Expertise

MeetMe, operator of the leading social network for meeting new people in the US and the public market leader for social discovery, today announced that Jason Whitt has been appointed to the company’s board of directors.

“We are excited to add Jason to our board of directors,” stated Geoff Cook, Chief Executive Officer of MeetMe. “Jason brings a strong product mindset and a wide variety of business development expertise. Jason’s background in mobile and digital media make him a strong addition to our board as we execute on our mobile growth plan. We look forward to many contributions to come.”

Mr. Whitt currently serves as Senior Vice President of Corporate and Business Development for ReachLocal, Inc., a leader in powering digital marketing for local businesses. Prior to that, he was with VantagePoint Venture Partners, where he focused on investments in Internet/digital media, cloud delivered software & services, mobile, consumer-oriented technology and healthcare IT. Prior to VantagePoint, Mr. Whitt was responsible for acquisitions, venture investing, and corporate strategy for Cisco Systems’ Corporate Business Development group, where he led numerous transactions involving communications software and applications, enterprise collaboration, mobile/wireless, Internet/digital media, and consumer technology companies.

Mr. Whitt commented, “MeetMe’s growing mobile traffic and revenue speak to the enormous opportunity to build a global brand for meeting new people. I am impressed by MeetMe’s focus on making it as easy as possible for mobile users to find new chat partners. I look forward to working with Geoff and the MeetMe team to capture the opportunity in front of us.”

The appointment of Mr. Whitt returns the board’s size to six members. Mr. Whitt replaces Alonso Ancira, who had served on MeetMe’s board from November 2006 until the Annual Meeting of stockholders held on August 11, 2014.

Posted in Small Cap News | Leave a comment

Stellar Biotechnologies, Inc. (SBOTF) Takes World Lead in Production of Key Immuno-Oncology Cancer Therapy Agent

There are four things you absolutely must know about Stellar Biotechnologies, the world leader in the sustainable production of immunization-grade Keyhole Limpet Hemocyanin (KLH) molecules. For those unfamiliar with KLH, it is used as an adjuvant and protein carrier in the rapidly growing field of Immuno-Oncology Cancer (IOC) Therapy.

1. Reporting on the 2014 meeting of the American Society of Clinical Oncology (ASCO), veteran biotechnology investment advisor John McCamant wrote that “the immuno-oncology sector is primed to become a super blockbuster market. Most current Wall Street estimates (placing) the immuno-oncology treatment space (at) $10–$15 billion are based on only a few cancer types (melanoma, NSCLC and renal) … but the signal at ASCO is that immuno-oncology, with all the new tools emerging, will impact the vast majority, if not virtually all, cancer types in some shape or form.”

2. The peptides, small proteins and drug molecules used in cancer vaccines and other immunological therapy agents are generally ineffective unless combined with a carrier protein capable of stimulating an intense immune response within the patient’s body. KLH, which generates a very powerful immune response, has quickly become the carrier protein of choice for most IOC applications.

3. Tests released by the National Center for Biotechnology Information show that KLH “has significant antiproliferative effects in vitro against breast cancer, pancreatic cancer, prostate cancer and Barrett’s esophageal cancer.” Numerous other studies, some as recent as last year and others dating back almost a decade, report similar findings.

4. Historically, the best, most potent source of vaccine-grade KLH has been the California Giant Keyhole Limpet. At the present time, Stellar Biotechnology’s aquaculture breeding and processing center in Port Hueneme, California is believed to be the world’s only dedicated facility for controlled spawning and development of the limpets in a safe, non-polluted environment. The combination limpet “incubator” and processing plant uses proprietary technology and Stellar’s patented non-lethal extraction process to produce proteins optimized for use as an essential part of many Immuno-Oncology therapies. The new facility has a spawning capacity of 2 million larvae and is designed to produce 50,000 juvenile limpets per year to support the increased demand for Stellar KLH products.

In addition to providing KLH as an adjuvant to other pharmaceutical companies’ immunization formulas, Stellar is heavily invested in developing its own end-to-end KLH-based therapies for specifically targeted conditions with a limited range of current treatment alternatives.

The first of these likely to reach market is an immunotherapy vaccine to prevent primary and secondary Clostridium difficile (C. diff) infections, which can, according to the Mayo Clinic, cause inflammation of the colon (colitis), patches of raw intestinal tissue that can bleed or become infested with pus and dehydration requiring hospitalization.

Stellar’s anti-C. diff agents are being produced under a worldwide license giving the company exclusive rights to develop, manufacture, and sell human C. diff vaccines derived from patented human immunotherapies discovered at the University of Guelph, Ontario. The license also awards Stellar similar rights in regard to using the patents to develop and market C. diff diagnostic aids.

“This opens significant new opportunities for Stellar and is an excellent fit in our goal to secure complementary technologies for strategic expansion,” said Frank R. Oakes, Stellar founder, president and CEO. “We hold the world’s leading technology for sustainable manufacture of KLH protein and now we have a strong platform for Stellar’s first proprietary, active immunotherapy program.”

Chief Technology Officer Herbert Chow, Ph.D., added that research done in conjunction with Guelph prior to the issuance of the license proved that “a PSII-KLH conjugate has the potential to be a major infectious disease immunotherapy” and noted that those research results plus the license “opens the door for a multitude of new uses for Stellar KLH technology.”

SBOTF’s corporate objectives are precise, clearly stated and well on the way to attainment. Its strategy, the company says, is “to produce, maintain and develop keyhole limpets through intellectual property and to continuously advance key IP to extract, purify and formulate KLH profitably, while increasing the number and maintaining the good health of the essential source animals.”

Another strategic initiative includes “marketing and selling the company’s formulations of KLH and (making) consistent efforts to expand markets, promote the use of KLH within the academic, research, pharmaceutical, biotech and medical diagnostic markets, and alone and in partnership with others, develop and sell as many proprietary KLH-based products as possible for the medical diagnostic and therapeutic markets.”

Commenting on Stellar’s impressive track record in achieving strategic partnerships with other Immuno-Oncology therapy pioneers, Oakes, a 30-year aquaculture industry veteran and developer of much of Stellar’s patented technology, noted that “this has been an important strategic year for Stellar … our corporate collaborations, where Stellar KLH is used as the critical carrier molecule in new therapeutic vaccines, are strong and poised for clinical advancement.”

The list of major stakeholders in the Immuno-Oncology space electing to become one of Stellar’s “corporate collaborators” is both impressive and growing.

Included is Bayer Innovation GmbH (BIG), which uses KLH as a key element in its personalized idiotype vaccine for the treatment of Non-Hodgkin’s Lymphoma. As part of its compensation, in addition to a cash payout, Stellar was granted an exclusive, irrevocable worldwide sub-licensable and royalty-free license to the technology developed through the collaboration. The license allows BIG to use the technology in the non-Hodgkin Lymphoma vaccine under development, but Stellar may exclusively commercialize the technology in all other applications.

Stellar is also partnering with the French biotechnology firm Neovacs SA, a pioneer in developing active immunotherapy solutions for autoimmune and inflammatory diseases, to provide its KLH/SUBUNIT extract for Neovacs’ trials of new vaccines for rheumatoid arthritis and Lupus.

Another collaboration is an exclusive manufacturing and supply agreement under which Life Diagnostics, a leading producer of medical testing and diagnostic kits and reagents, will use Stellar KLH to develop and manufacture Stellar-brand test kits for the detection of anti-KLH antibodies for use by immunotoxicity and immunology researchers.

Stellar has also entered into an agreement with the SAFC division of Sigma Aldrich, a highly respected international vendor of specialty chemicals and biologics for commercial life science applications. Under the terms of the contract, SAFC will “sell, distribute and market” Stellar’s high molecular weight keyhole limpet hemocyanin (HMW KLH) for application in therapeutic vaccines.

In addition to partnering with world-class pharmaceutical companies and research institutions, SBOTF has received research and other grants from the National Science Foundation, the National Institute of Health’s Center for Research Resources, the California Technology Investment Partnership and the Internal Revenue Service’s Therapeutic Discovery Project Program.

Ranked number one across all five industry sectors of the 2014 TSX Venture 50®, an elite listing of top companies traded on the Toronto Stock Exchange’s sister exchange, the TSX Venture Exchange, SBOTF’s bottom-line is showing significant growth for a company almost obsessively invested in research and development. Quarter-to-quarter revenues for Q3 of the 2014 fiscal year ending in August jumped 140 percent to $102,500, while R&D spending went from $178,000 in Q3 2013 to $462,129 in 2014, largely due to development costs associated with the C. diff vaccine manufacturing process.

According to numerous studies published by the National Institute of Health and other government and private research institutes, one of the greatest potential uses of Immuno-Oncology is to help us learn how cancer bypasses the immune system and how to create new chemical barriers to close that lethal “loophole.” With the eventual goal the restoration of the body’s ability to rid itself of tumors, the demand for Stellar Biotechnologies’ KHL, KLH/SUBUNIT and other limpet-based products could potentially develop into one of those highly prized but infrequently encountered rarities known as a virtually no-limits market.

Let us hear your thoughts below:

Posted in Small Cap News | Leave a comment